Placebo News and Research

RSS

Hearing loss and sex shape dual-task outcomes in older adults with mild cognitive impairment

Cognitive and physical training can help older adults with mild cognitive impairment (MCI) maintain or improve their ability to move and think simultaneously, but hearing ability and sex influence outcomes, according to a new Concordia-led study.

7 Apr 2026

What happens in the brain on psychedelics? Scientists identify a common circuit pattern

Researchers combined 11 international resting-state fMRI datasets to map how psychedelic drugs reshape brain connectivity across cortical and subcortical circuits. The mega-analysis found a shared signature of stronger coupling between transmodal association networks and unimodal or sensorimotor systems, alongside selective and variable reductions in within-network connectivity.

7 Apr 2026

Evolocumab trial could reshape how doctors treat high-risk cholesterol patients

A new ACC/AHA dyslipidemia guideline and editorial argue that guideline development is rigorous but can lag behind fast-moving science, using the VESALIUS-CV trial as a clear example. The trial showed that intensive LDL cholesterol lowering with evolocumab reduced cardiovascular events in high-risk patients without prior heart attack or stroke, with implications for future guideline updates.

6 Apr 2026

Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)

NICE has recommended Wegovy® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m2).

From Novo Nordisk 2 Apr 2026

Kinesio taping offers limited benefits for treating musculoskeletal pain and mobility

Kinesio taping, or 'KT tape' as it's usually known-widely used to ease joint/muscle pain and boost range of movement-may not be all that effective, suggests a pooled data analysis of the existing evidence, published in the online journal BMJ Evidence Based Medicine.

1 Apr 2026

Treating autonomic dysfunction can relieve symptoms of treatment-resistant depression

Consider a house with the water main half shut. The faucets sputter. The toilet runs all night. The garden wilts. You could call a plumber for the faucet, a landscaper for the garden, a different plumber for the toilet, and every one of them would fix something while fixing nothing.

31 Mar 2026

Why vaginal microbiota transplants aren’t working yet

Vaginal microbiota transplantation without antibiotics fails to restore microbiome balance, yet engraftment suggests avenues for enhancing treatment efficacy.

31 Mar 2026

Vaping beats traditional tools for quitting smoking

The review indicates nicotine e-cigarettes could surpass traditional quit aids in effectiveness, but lingering safety uncertainties warrant further research.

31 Mar 2026

Antidepressant fluvoxamine reduces long COVID fatigue in clinical trial

A randomized placebo-controlled trial found that fluvoxamine, a low-cost antidepressant, reduced fatigue and improved quality of life in adults with long COVID, offering one of the first evidence-based medication options for this persistent condition. In contrast, metformin did not provide meaningful benefit for established long COVID fatigue, highlighting fluvoxamine as the more promising treatment candidate in this study.

30 Mar 2026

Triglyceride-lowering drug olezarsen fails to reduce arterial plaque

Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of atherosclerosis did not experience any significant change in the amount of non-calcified plaque in their coronary arteries after taking the triglyceride-lowering drug olezarsen, in a one-year sub-study presented at the American College of Cardiology's Annual Scientific Session.

30 Mar 2026

Digoxin found safe to use in young patients with rheumatic heart disease

Patients with rheumatic heart disease who took the heart failure drug digoxin were 18% less likely to die or experience new-onset or worsening heart failure during a two-year follow-up compared with those who received a placebo, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

30 Mar 2026

Taking a placebo knowingly still improves stress and memory

Research indicates open-label placebos can ease stress and boost memory in older adults, presenting a novel, ethical strategy for promoting healthy aging.

30 Mar 2026

New drug sotatercept shows benefit in CpcPH-HFpEF patients

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and vascular health after taking the drug sotatercept, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Trial shows mavacamten benefits adolescents with obstructive heart condition

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Angioplasty improves symptoms in chronic total coronary occlusion patients

In what is believed to be the first randomized placebo-controlled trial of its kind, patients with a chronic total blockage of a coronary artery who received a nonsurgical procedure to reopen the artery showed statistically significant reductions in chest pain and improvements in quality of life compared with patients who received a placebo procedure.

29 Mar 2026

Evolocumab reduces cardiac events in high-risk diabetic patients

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026

Investigational drug lowers angiotensinogen but shows unclear blood pressure benefits

The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that turns into the hormone that regulates blood pressure—caused a significant and sustained drop in angiotensinogen but its impact on blood pressure was less clear, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026

Intensive cholesterol‑lowering therapy reduces first major cardiac event in high‑risk patients with diabetes

Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes.

28 Mar 2026

Study reveals how a promising bacterial therapy reduces recurrent bacterial vaginosis

A new study from the Kwon Lab at the Ragon Institute, published in Cell Host & Microbe, provides the most detailed picture yet of how a promising bacterial therapy works to prevent recurrent bacterial vaginosis (BV) and why it works better for some women than others.

27 Mar 2026

Nicotine e-cigarettes outperform other methods for quitting smoking

A new analysis of existing studies co-led by a University of Massachusetts Amherst public health researcher finds that nicotine e-cigarettes consistently help adults quit smoking, a conclusion that emerges with striking agreement across nearly a decade of studies.

26 Mar 2026

Placebo News and Research

Hearing loss and sex shape dual-task outcomes in older adults with mild cognitive impairment

What happens in the brain on psychedelics? Scientists identify a common circuit pattern

Evolocumab trial could reshape how doctors treat high-risk cholesterol patients

Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)

Kinesio taping offers limited benefits for treating musculoskeletal pain and mobility

Treating autonomic dysfunction can relieve symptoms of treatment-resistant depression

Why vaginal microbiota transplants aren’t working yet

Vaping beats traditional tools for quitting smoking

Antidepressant fluvoxamine reduces long COVID fatigue in clinical trial

Triglyceride-lowering drug olezarsen fails to reduce arterial plaque

Digoxin found safe to use in young patients with rheumatic heart disease

Taking a placebo knowingly still improves stress and memory

New drug sotatercept shows benefit in CpcPH-HFpEF patients

Trial shows mavacamten benefits adolescents with obstructive heart condition

Angioplasty improves symptoms in chronic total coronary occlusion patients

Evolocumab reduces cardiac events in high-risk diabetic patients

Investigational drug lowers angiotensinogen but shows unclear blood pressure benefits

Intensive cholesterol‑lowering therapy reduces first major cardiac event in high‑risk patients with diabetes

Study reveals how a promising bacterial therapy reduces recurrent bacterial vaginosis

Nicotine e-cigarettes outperform other methods for quitting smoking

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News